CareDx Q4 2023 Adj EPS $(0.17) Beats $(0.27) Estimate, Sales $65.57M Beat $63.66M Estimate
Portfolio Pulse from Benzinga Newsdesk
CareDx (CDNA) reported Q4 2023 adjusted EPS of $(0.17), surpassing the $(0.27) estimate, with sales of $65.57M exceeding the $63.66M forecast. However, this represents a 20.41% decrease in sales compared to the same period last year.
February 28, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CareDx reported better-than-expected Q4 2023 earnings and sales, with an adjusted EPS of $(0.17) and sales of $65.57M, beating estimates. However, sales decreased by 20.41% compared to last year.
CareDx's better-than-expected earnings and sales for Q4 2023 are likely to positively impact investor sentiment in the short term, despite the year-over-year decrease in sales. The significant beat on both the top and bottom lines indicates operational efficiency and could lead to a positive reevaluation of the stock by the market. However, the decrease in sales year-over-year might temper some of the positive momentum.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100